An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
BioNxt says it’s moving forward on a project to make semaglutide — the drug in Ozempic and Wegovy — into a thin tablet that dissolves under the tongue (an oral dissolving film). In plain terms, the company announced it has completed an early stage of developing this new way to deliver the drug and is starting the next phase of work on the delivery method. Semaglutide is a man-made copy of a natural hormone that helps control appetite and blood sugar. Right now it’s most commonly given as a weekly injection for diabetes and as a branded drug for weight loss. The idea behind an oral dissolving film is to let patients take the medicine without a needle — the strip would be placed under the tongue and dissolve, letting the drug be absorbed through the mouth lining. The announcement is about BioNxt advancing the delivery technology, not about a new proof that the strip works in people yet. The company is describing progress in development, which typically means lab work and formulation steps rather than large human trials. The snippet doesn’t include results from clinical studies, numbers on how well the drug is absorbed, or safety data, so we don’t know yet if the strip delivers the same amount of active drug as the injections or how well it controls blood sugar or weight. Why this matters is straightforward: many people who need semaglutide dislike injections or find them inconvenient. A dissolving strip could make the medication easier to use and broaden access for people who avoid needles. If it works the same as current versions, it could improve adherence (people actually taking their medicine) and make treatment feel less medical and more convenient. There are important caveats. Turning an injected drug into a form that works under the tongue is technically challenging; absorption through the mouth is different from injections and the gut. The announcement doesn’t say the strip has been tested in humans or approved by regulators. Side effects associated with semaglutide — like nausea, digestive upset, and rare but serious risks — would likely still apply, and dosing could change. Until there are published clinical trial results and regulatory approval, this is promising development news, not a ready product. Bottom line: BioNxt reports progress toward a semaglutide strip that dissolves under the tongue, but we don’t yet have human proof that it’s safe and effective compared with the injected versions.
Source: ACCESS Newswire